Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG is conducting a Phase 3 clinical trial titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease. The study aims to evaluate the effectiveness and safety of finerenone, a drug designed to slow the progression of non-diabetic chronic kidney disease (CKD) by blocking the hormone aldosterone, which contributes to kidney and heart inflammation.
The intervention being tested is finerenone, administered as a daily oral tablet, compared to a placebo. Finerenone is intended to help manage CKD by reducing inflammation and injury in the kidneys.
The study is interventional with a randomized, double-blind, placebo-controlled, parallel-group design. Participants and investigators are unaware of the treatment allocations, ensuring unbiased results. The primary purpose is treatment-focused.
The trial began on September 21, 2021, and is not currently recruiting. The last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
This update could positively impact Bayer’s stock performance by showcasing its commitment to advancing treatments for CKD, potentially enhancing investor confidence. The competitive landscape in CKD treatments might influence market dynamics, but Bayer’s progress could position it favorably.
The study is ongoing, with further details available on the ClinicalTrials portal.